• Explore /
  • Poster
  • / PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC).

PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC).

Abstract Poster

Authors

Martin Voss

Martin H Voss

Memorial Sloan Kettering Cancer Center, New York, NY

Martin H Voss , Scott S. Tykodi , Marc-Oliver Grimm , Hans J. Hammers , Brian I. Rini , Nizar M. Tannir , Anila H. Qureshi , Vicky Tsipouri , Moana Hodari , Shruthi Ravimohan , Melissa Andrea Reimers

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04540705

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS403)

DOI

10.1200/JCO.2022.40.6_suppl.TPS403

Abstract #

TPS403

Poster Bd #

M12

Abstract Disclosures

Similar Posters

First Author: Matthew R. Zibelman

First Author: Bridget Keenan

First Author: Toni K. Choueiri

First Author: Michael B. Atkins